Peptide
Ipamorelin
SaveA selective growth-hormone secretagogue pentapeptide that stimulates GH release with minimal effect on cortisol, prolactin, and appetite compared to other GHRPs.
Quick verdict
Considered the most selective GHRP available. Popular in anti-aging clinics for its clean side-effect profile. Not FDA-approved.
Evidence score
A rough internal score reflecting quantity, quality, and consistency of human evidence. Not a clinical recommendation.
What the research shows
Human studies confirm GH release with minimal cortisol/prolactin elevation. No desensitization observed in available data. Phase II trial for post-operative ileus was conducted.
Benefits
- Selective GH release without significant cortisol or prolactin increase
- Minimal appetite stimulation compared to GHRP-6
- No observed desensitization with repeated dosing
Dosage notes
Typical clinic protocols: 100–300 mcg subcutaneously at bedtime. Often combined with CJC-1295.
Side effects
- Mild water retention
- Injection-site reactions
- Occasional headache
- Transient numbness or tingling
Who should be cautious
Not FDA-approved. Long-term safety of chronic GH stimulation remains a concern.
What this page cannot tell you
Clinical outcome data (body composition, aging) are limited despite good pharmacologic characterization.
Leaderboard scores
- Muscle38
- Recovery35
- Sleep25
- Longevity22
Write a review
Sign in to write a review.